# UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA

NUVASIVE, INC.,

Plaintiff.

Defendant.

Case No.: 3:18-CV-347-CAB-MDD

## ORDER DENYING MOTION FOR PRELIMINARY INJUNCTION

[Doc. No. 37]

On February 13, 2018, Plaintiff NuVasive, Inc., filed a complaint alleging patent infringement against Defendants Alphatec Holdings, Inc., and Alphatec Spine, Inc., (jointly "Alphatec"). [Doc. No. 1.] The complaint asserts infringement of six patents: U.S. Patent No. 7,819,801; U.S. Patent No. 8,335,780; U.S. Patent No. 8,439,832; U.S. Patent No. 9,833,227; U.S. Patent No. 8,735,270; and U.S. Patent No. 8,361,156. The '801, '780, '832, '227 and '270 patents are directed toward systems and methods for accessing a targeted disc space through a lateral, trans-psoas path ("the Access Platform patents"). The '156 patent describes a spinal implant that is introduced into the disc space of a patient's spine from a lateral approach ("the Implant patent"). [Doc. No. 38, at 8-9.]<sup>2</sup>

On April 5, 2018, NuVasive filed a motion for preliminary injunction. [Doc. No. 37; Doc. No. 38 (sealed version).] NuVasive seeks to enjoin sales and use of the accused

26

27

28

25

<sup>&</sup>lt;sup>2</sup> Document numbers and page references are to those assigned by CM/ECF for the docket entry.



<sup>&</sup>lt;sup>1</sup> The complaint also asserted infringement of two design patents, but the Court granted Alphatec's motion to dismiss those claims with prejudice. [Doc. No. 45.]

Battalion™ Lateral System, which includes the Squadron™ Lateral Retractor, and the Battalion™ Lateral Spacer, during the pendency of the litigation. The parties filed a joint request on April 12, 2018, to extend the briefing schedule to allow for discovery. [Doc. No. 39.] Alphatec filed its opposition on May 17, 2018. [Doc. No. 49, Doc. No. 53 (sealed version).] NuVasive filed a reply on June 14, 2018. [Doc. No. 77, Doc. No. 79 (sealed version).] A hearing on the motion was held on June 21, 2018. [Doc. No. 87.] For the reasons set forth on the record at the hearing and as discussed below, the motion is DENIED.

### I. Background

NuVasive is a medical device company with over \$1 billion in annual revenues. In 2003, NuVasive launched a minimally-invasive, lateral access surgical procedure for spinal surgery, known as XLIF. The patented procedures and tools utilized in XLIF surgery, including the MaXcess® retractor and CoRoent® XLIF implants, allow for a lateral approach to a patient's targeted spinal disc space through the psoas muscle and for the delivery of a large, oversized implant for spinal fusion. [Doc. No. 38, at 6-7.] For over a decade, NuVasive has developed, patented and marketed the XLIF procedure and components. This product line now accounts for conservatively \$250-300 million of NuVasive's annual revenue. [Id., at 8.]

In approximately July 2014, Alphatec began developing a competing lateral access surgical procedure that became known as its Battalion Lateral System. On April 5, 2016, Alphatec submitted the accused components and procedure for FDA approval, which it received on September 8, 2016. On February 14, 2017, Alphatec made its first sale and public surgical use of the accused components. [Doc. No. 79-4, at 7.] In April 2017, Alphatec launched a limited release of the Battalion Lateral System. Alphatec made a full launch in October 2017. [Doc. No. 1, ¶ 43.] NuVasive now seeks to enjoin Alphatec from making, using, selling, offering to sell, or importing into the United States the components of Alphatec's Battalion Lateral System, specifically the Squadron Lateral Retractor,

Dilators, K-Wire, Intradiscal Shim and Shim Inserter Tool, 4th Blade and Light Cable/Light Source Connector; and Alphatec's Battalion Lateral Spacer.

### II. Legal Standard

The grant or denial of a preliminary injunction under 35 U.S.C. § 283 is within the sound discretion of the district court. *Amazon.com, Inc. v. Barnesandnoble.com, Inc.*, 239 F.3d 1343, 1350 (Fed. Cir. 2001). "A preliminary injunction is an extraordinary remedy never awarded as a matter of right." *Winter v. Natural Resources Defense Council*, 555 U.S. 7, 24 (2008). "A plaintiff seeking a preliminary injunction must establish that [it] is likely to succeed on the merits, that [it] is likely to suffer irreparable harm in the absence of preliminary relief, that the balance of equities tips in [its] favor, and that an injunction is in the public interest." *Id.* at 20. The district court must weigh and measure each factor against the other factors and against the form and magnitude of the relief requested. "[A] movant cannot be granted a preliminary injunction unless it establishes *both* of the first two factors, *i.e.* likelihood of success on the merits and irreparable harm." *Amazon.com*, 239 F.3d at 1350.

### III. Likelihood Of Success On The Merits

To demonstrate a likelihood of success on the merits, the movant must show that it will likely prove infringement of one or more claims of the asserted patents and that at least one of the same allegedly infringed claims will also likely withstand the validity challenges presented by the accused infringer. *See Amazon.com*, 239 F.3d at 1350-51 (holding that if the non-movant raises a substantial question concerning either infringement or validity that the patentee cannot prove "lacks substantial merit," the preliminary injunction should not issue). Thus, in considering NuVasive's motion, the Court must assess infringement claims made by NuVasive as well as any invalidity arguments made by Alphatec.

## A. Infringement

The burden lies with the patentee to establish that the accused product infringes by a preponderance of the evidence. An infringement analysis involves two steps. First, the claim scope must be determined. Second, the properly construed claim is compared with the accused devices to determine whether all the claim limitations are present either literally or by a substantial equivalent. *Amazon.com*, 239 F.3d at 1351.

NuVasive asserts the Access Platform patents against Alphatec's Battalion Lateral System and the Implant patent against the Battalion Lateral Spacer. A demonstration of the likelihood of a finding of infringement as to an asserted independent claim of any of the following patents could support NuVasive's request to enjoin the sale of the Battalion Lateral System: the '801 Patent (System Claim 1); the '780 Patent (System Claim 21); the '832 Patent (System Claim 1 or Method Claim 12); and the '227 Patent (Method Claims 1 or 16).<sup>3</sup> In response to the Court's request that NuVasive select the claim it considers best demonstrates its burden on infringement and validity [Doc. No. 86], NuVasive elected to proceed at argument on Claim 1 of the '832 patent and Claim 1 of the '156 patent.

## Claim 1 of the '832 Patent

The '832 Patent is for a Surgical Access System and Related Methods. [Doc No. 1-8, at 2-34.] It is directed at a system for establishing an operative corridor to the spine through the psoas muscle. Claim 1 claims:

1. A system for forming an operating corridor to a lumbar spine, comprising: a distraction assembly to create a tissue distraction corridor in a lateral, transpsoas path to a lumbar spine, wherein said distraction assembly includes an elongate inner element and a plurality of dilators, the plurality of dilators being configured to sequentially advance along the lateral, trans-psoas path to the lumber spine, the elongate inner element being positionable in a lumen of an initial dilator of the plurality of dilators, wherein at least one instrument from the group consisting of said elongate inner element and said dilators includes a stimulation electrode that outputs electrical stimulation for nerve monitoring when the at least one instrument is positioned in the psoas muscle;

<sup>&</sup>lt;sup>3</sup> The asserted claims of '270 Patent allegedly cover the accused Alphatec Intradiscal Shim device. [Doc. No. 1-12, at 32, Col. 14:30-61.] A finding of a likelihood of infringement of the asserted claims would not support the request to enjoin sales or use of the whole Battalion Lateral System or the Squadron Retractor, just that component.



a three-bladed retractor tool slidable over an exterior of an outermost sequential dilator of the dilator system toward the targeted spinal disc along the lateral, trans-psoas path, the three-bladed retractor assembly including:

a blade-holder assembly, and

a posterior-most retractor blade, a cephalad-most retractor blade, and a caudal-most retractor blade that extend from the blade-holder assembly, wherein the posterior-most, cephalad-most, and caudal-most retractor blades are slideably advanced over the exterior of the outermost sequential dilator while in a first position, wherein the blade-holder assembly is adjustable to move the posterior-most, cephalad-most, and caudal-most retractor blades to a second position in which the cephalad-most and caudal-most retractor blades are spaced apart from the posterior-most retractor blade to define an operative corridor,

wherein three-bladed retractor tool is configured to define the operative corridor along the lateral, trans-psoas path to the lumber spine in which a space extending to the targeted spinal disc between the posterior-most, cephalad-most, and caudal-most refractor blades is dimensioned so as to pass an implant through the operative corridor along the lateral, trans-psoas path to the lumbar spine.

[Doc. No. 1-8, at 31-32, Col. 14:31- Col. 15:3.]

NuVasive alleges that the limitations of Claim 1 of the '832 patent read on Alphatec's Battalion Lateral System. *See* Declaration of Jim A. Youseff, M.D., ¶¶ 171-191, and Appendix C. [Doc. No. 37-45, at 70-74; Doc. No. 37-71, at 2-21.] Referencing the <u>Alphatec Battalion Lateral Lumbar Spacer System Thoracolumbar Surgical Technique Guide</u> and devices disclosed therein, [Doc. No. 1-38, at 2-30], NuVasive demonstrated that the Battalion Lateral System: (1) forms an operative corridor to the patient's lumbar spine through the psoas muscle; (2) uses an initial dilator with neuromonitoring to traverse the psoas to the disc space; (3) introduces a K-wire (elongate inner element) through the initial dilator into the disc space; (4) introduces a secondary sequential dilator over the initial dilator [Id., at 7-9]; and (5) introduces a retractor, called the Squadron Retractor, over the second dilator and moves it flush to the disc space [Id., at 11.] The Squadron Retractor is a tool with a blade-holder assembly and three blades, center, right and left. [Id., at 15, 17,

# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

